Meritage Portfolio Management Has $212,000 Stock Holdings in Novo Nordisk A/S $NVO

Meritage Portfolio Management decreased its position in Novo Nordisk A/S (NYSE:NVO) by 97.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,819 shares of the company’s stock after selling 148,831 shares during the quarter. Meritage Portfolio Management’s holdings in Novo Nordisk A/S were worth $212,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Lockheed Martin Investment Management Co. raised its holdings in shares of Novo Nordisk A/S by 179.4% in the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after buying an additional 27,900 shares in the last quarter. Martin Capital Partners LLC grew its position in Novo Nordisk A/S by 53.8% in the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares during the period. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Novo Nordisk A/S during the third quarter worth $1,294,000. Unified Investment Management acquired a new position in Novo Nordisk A/S during the second quarter worth $692,000. Finally, Guild Investment Management Inc. raised its stake in Novo Nordisk A/S by 20.7% during the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock worth $2,553,000 after acquiring an additional 6,345 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.
• Positive Sentiment: Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.
• Positive Sentiment: U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.
• Neutral Sentiment: Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.
• Neutral Sentiment: High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.
• Negative Sentiment: Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.
• Negative Sentiment: Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.

Novo Nordisk A/S Price Performance

NVO opened at $62.32 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The stock has a market capitalization of $278.26 billion, a P/E ratio of 18.12 and a beta of 0.66. The company’s 50 day simple moving average is $50.85 and its 200-day simple moving average is $55.08. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NVO shares. The Goldman Sachs Group lowered their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $56.21.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.